25th May 2006 15:23
Hikma Pharmaceuticals Plc25 May 2006 Hikma Pharmaceuticals PLC - Results of Annual General Meeting LONDON, 25 May 2006 - Hikma Pharmaceuticals PLC ("the Company") advises that atits Annual General Meeting of shareholders, held at the London UnderwritingCentre, that began at 11.00am today, 25 May 2006, resolutions 1 to 12 containedin the Notice of Annual General Meeting were passed as ordinary resolutions on ashow of hands, resolutions 13 and 14 were passed as special resolutions on ashow of hands, and resolution 15 was passed as an ordinary resolution by way ofa poll. The results of the poll are set out below: Resolution 15 For AgainstWaiver of Rule 9 of the City Code on 36,581,606 2,561,802Takeovers and Mergers Copies of the resolutions dealing with special business passed at the AnnualGeneral Meeting have been submitted to the UK Listing Authority for publicationthrough the Listing Authority's Document and Viewing Facility. The total number of proxies received for each resolution is set out below. Resolutions For Against Vote withheld 1 Receipt of accounts, together with 92,636,850 2,327,413 311,000 reports of the Directors and auditors 2 Declaration of final dividend 95,275,263 - - 3 Reappointment of Mr Samih Darwazah 91,748,810 3,240,853 285,600 as a Director of the Company 4 Reappointment of Mr Mazen Darwazah 92,879,942 2,309,213 86,108 as a Director of the Company 5 Reappointment of Mr Ali Al-Husry as a 95,257,063 18,200 - Director of the Company 6 Reappointment of Mr Michael Ashton as a 95,275,263 - - Director of the Company 7 Reappointment of Mr Breffni Byrne as a 95,275,263 - - Director of the Company 8 Reappointment of Sir David Rowe-Ham as a 95,275,263 - - Director of the Company 9 Reappointment of Deloitte & Touche as 95,037,639 90,528 147,096 auditors of the Company 10 Authorise the Directors to set the 95,257,063 18,200 - remuneration of the auditors 11 Approval of the Board report on 89,267,907 2,930,733 3,076,623 remuneration 12 Authorise the Directors to allot relevant 95,103,719 880 170,664 securities up to an aggregate nominal amount of £5,559,947 13 Empower the Directors to allot equity 95,103,719 880 170,664 securities for cash on a non pre-emptive basis up to an aggregate nominal amount of £833,992 14 Cancellation of unissued unclassified 95,104,599 - 170,664 shares 15 Waiver of Rule 9 of the City Code on 36,571,606 2,561,802 3,279,631 Takeovers and Mergers The number of 10p ordinary shares in issue on 25 May 2006 was 167,287,607. Waiver of Rule 9 of the City Code on Takeovers and Mergers In relation to Resolution 15, at today's date, the total number of ordinaryshares held by the Concert Party, is 60,446,652, representing a combinedshareholding of 36.133% of the issued share capital of the Company. If all ofthe options held by members of the Concert Party are exercised and the sharecapital of the Company is not otherwise increased, the number of ordinary sharesheld by the Concert Party will increase to 62,966,652, representing 37.081% ofthe enlarged issued share capital of the Company. Declaration of final dividend The final dividend of 0.89 cents per share will be paid on 30 May 2006 toshareholders on the register on 28 April 2006. Shareholders who are not residentin Jordan have been given the option of receiving their dividend in PoundsSterling. The exchange rate in respect of this dividend is 1.8755 US dollars toone Pound Sterling, equal to 0.47 pence per share. Shareholders resident inJordan have been given the opportunity to receive the dividend in JordanianDinar, at a rate of 0.708 Jordanian Dinar per US dollar. - ENDS - Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2670Company SecretarySusan Ringdal +44 20 7399 2670Investor Relations Director Brunswick Group Jon Coles / Wendel Verbeek / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals